Managing a Portfolio of Interdependent New Product Candidates in the Pharmaceutical Industry
- 2 July 2004
- journal article
- Published by Wiley in Journal of Product Innovation Management
- Vol. 21 (4) , 227-245
- https://doi.org/10.1111/j.0737-6782.2004.00075.x
Abstract
Highly regulated industries such as pharmaceuticals and agrochemicals face the challenge of maintaining a 0continuous stream of new products. This is difficult because of low probabilities of technical success, high development costs, uncertain market impact, a scarcity of good new product ideas, and limited human and capital resources available to develop them. The problem of evaluating and selecting which new products to develop and then of sequencing or of scheduling them is complicated further by the presence of dependencies between products both in the market place and in the development process itself.This study proposes a portfolio management approach that selects a sequence of projects, which maximizes the expected economic returns at an acceptable level of risk for a given level of resources in a new product development pipeline. A probabilistic network model of distinct activities is used to capture all the activities and resources required in the “process” of developing a new drug. A prioritization scheme suggesting sequences for developing new independent drug candidates with unlimited resources is generated with a conventional bubble chart approach. These sequences initiate a genetic algorithm (GA)‐based search for the optimal sequence in the presence of product dependencies and limited resources. By statistically evaluating the sequences generated during the GA search using a discrete event simulation model, it is possible to construct an economic reward‐risk frontier that illustrates the trade‐offs between expected rewards and risks. The model ideally is suited to answer various “what if” questions relative to changes in the resource level on pipeline performance.The methodology is illustrated with an industrially motivated case study, involving nine interdependent new product candidates targeting three diseases. The dramatic results yield a candidate sequence with an expected return 28 percent higher than the sequence suggested by the bubble chart approach at almost the same level of risk. The synergism among the candidate dependencies, pipeline resources, and economic and technical uncertainties demonstrates the necessity of a computationally intensive approach if the best development strategy is to be realized.Keywords
This publication has 20 references indexed in Scilit:
- Toward a theory of project interdependencies in high tech R&D environmentsJournal of Operations Management, 2002
- An exploratory Investigation of new product forecasting practicesJournal of Product Innovation Management, 2002
- Understanding fire fighting in new product development⋆Journal of Product Innovation Management, 2001
- Evaluating growth options as sources of value for pharmaceutical research projectsR&D Management, 2001
- A comparative analysis of R&D project evaluation methodsR&D Management, 2001
- New Product Portfolio Management: Practices and PerformanceJournal of Product Innovation Management, 1999
- PDMA Research on New Product Development Practices: Updating Trends and Benchmarking Best PracticesJournal of Product Innovation Management, 1997
- Industrial New Product Launch Strategies and Product Development PerformanceJournal of Product Innovation Management, 1997
- Changing Patterns in Industrial R&D ManagementJournal of Product Innovation Management, 1996
- Implementing a Stage‐Gate Process: A Multi‐Company PerspectiveJournal of Product Innovation Management, 1994